Value Proposition
· Purified EVs with preferential targeting for B cells in both ex-vivo and in-vivo applications.
· EVs have half-life between 30-40 minutes, longer than many comparable extracellular vesicles.
· EVs purified from cell culture medium to increase throughput, speed, and development of B-cell targeted therapies.
Technology Description
Researchers at Johns Hopkins have developed culture-derived extracellular vesicles (EVs) that differentially target B cells useful to effectively deliver treatments for B-cell associated diseases. Cell culture-derived EVs were isolated using a combination of tangential flow filtration, size-exclusion chromatography, and centrifugal filtration. As demonstrated in ex vivo and in vivo studies labeled EVs preferentially bind to B cells. Therefore, the disclosed process can be exploited as a platform to treat B cell diseases through targeted delivery, including treatment of autoimmune diseases and cancer.
Unmet Need
Extracellular vesicles are increasingly regarded as promising delivery vehicles for various therapeutic cargoes, however, lack of understanding of the pharmacokinetic and biodistribution properties and resulting off-target effects are hindering clinical translation of EVs. Therefore, there is a need for EVs with improved cell-specificity and half-life for therapeutic applications.
Stage of Development
in vivo experiments have demonstrated successful B-cell targeting and uptake.
Data Availability
Data available upon request.
Publication
Driedonks T, Jiang L, Carlson B, Han Z, Liu G, Queen SE, Shirk EN, Gololobova O, Liao Z, Nyberg LH, Lima G, Paniushkina L, Garcia-Contreras M, Schonvisky K, Castell N, Stover M, Guerrero-Martin S, Richardson R, Smith B, Machairaki V, Lai CP, Izzi JM, Hutchinson EK, Pate KAM, Witwer KW. Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina. J Extracell Biol. 2022 Oct;1(10):e59. doi: 10.1002/jex2.59. Epub 2022 Oct 11. PMID: 36591537; PMCID: PMC9799283.
